These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19240791)

  • 1. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis.
    Graubert TA; Payton MA; Shao J; Walgren RA; Monahan RS; Frater JL; Walshauser MA; Martin MG; Kasai Y; Walter MJ
    PLoS One; 2009; 4(2):e4583. PubMed ID: 19240791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes.
    MacKinnon RN; Kannourakis G; Wall M; Campbell LJ
    Cancer Genet; 2011 Apr; 204(4):187-94. PubMed ID: 21536236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears.
    Bigoni R; Cuneo A; Milani R; Cavazzini F; Bardi A; Roberti MG; Agostini P; della Porta M; Specchia G; Rigolin GM; Castoldi G
    Haematologica; 2001 Apr; 86(4):375-81. PubMed ID: 11325642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
    Horrigan SK; Westbrook CA; Kim AH; Banerjee M; Stock W; Larson RA
    Blood; 1996 Oct; 88(7):2665-70. PubMed ID: 8839861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of 5q31 is observed in megakaryocytic cells in patients with myelodysplastic syndromes and a del(5q), including the 5q- syndrome.
    Godon C; Talmant P; Garand R; Accart F; Bataille R; Avet-Loiseau H
    Genes Chromosomes Cancer; 2000 Dec; 29(4):350-2. PubMed ID: 11066080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
    Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
    Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion 5q MDS: molecular and therapeutic implications.
    Komrokji RS; Padron E; Ebert BL; List AF
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular dissection of the 5q deletion in myelodysplastic syndrome.
    Ebert BL
    Semin Oncol; 2011 Oct; 38(5):621-6. PubMed ID: 21943668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
    Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
    Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
    Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
    Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.
    Le Beau MM; Espinosa R; Neuman WL; Stock W; Roulston D; Larson RA; Keinanen M; Westbrook CA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5484-8. PubMed ID: 8516290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice.
    Chen TH; Kambal A; Krysiak K; Walshauser MA; Raju G; Tibbitts JF; Walter MJ
    Blood; 2011 Feb; 117(5):1530-9. PubMed ID: 21123823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.
    Evers C; Beier M; Poelitz A; Hildebrandt B; Servan K; Drechsler M; Germing U; Royer HD; Royer-Pokora B
    Genes Chromosomes Cancer; 2007 Dec; 46(12):1119-28. PubMed ID: 17823930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
    Hosono N; Makishima H; Mahfouz R; Przychodzen B; Yoshida K; Jerez A; LaFramboise T; Polprasert C; Clemente MJ; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Cui E; Verma AK; McDevitt MA; List AF; Saunthararajah Y; Sekeres MA; Boultwood J; Ogawa S; Maciejewski JP
    Oncotarget; 2017 Jan; 8(4):6483-6495. PubMed ID: 28031539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genetic defects of chromosome 5q and 7q in myeloid neoplasms].
    Hosono N
    Rinsho Ketsueki; 2019; 60(7):800-809. PubMed ID: 31391370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome.
    Jaju RJ; Boultwood J; Oliver FJ; Kostrzewa M; Fidler C; Parker N; McPherson JD; Morris SW; Müller U; Wainscoat JS; Kearney L
    Genes Chromosomes Cancer; 1998 Jul; 22(3):251-6. PubMed ID: 9624537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletions of chromosome 5 in malignant myeloid disorders.
    Le Beau MM
    Cancer Surv; 1992; 15():143-59. PubMed ID: 1451109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
    Eisenmann KM; Dykema KJ; Matheson SF; Kent NF; DeWard AD; West RA; Tibes R; Furge KA; Alberts AS
    Oncogene; 2009 Oct; 28(39):3429-41. PubMed ID: 19597464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.